Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drugs for rare and end-of-life conditions get Scottish cash boost

This article was originally published in Scrip

Executive Summary

The Scottish government has allotted £80m to the New Medicines Fund, which is used to help pay for treatments for patients with rare or end-of-life conditions, for 2015-16. This is double the amount given to the fund in the previous year, and will help pay for the expected rise in the number of such products being recommended by the HTA body, the Scottish Medicines Consortium (SMC).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts